These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 31383734)

  • 1. Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate.
    Willis JA; Reyes-Uribe L; Chang K; Lipkin SM; Vilar E
    Clin Cancer Res; 2020 Jan; 26(1):11-17. PubMed ID: 31383734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA mismatch repair in cancer.
    Baretti M; Le DT
    Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
    Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
    J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
    Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
    JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
    Jin Z; Sinicrope FA
    J Clin Oncol; 2022 Aug; 40(24):2735-2750. PubMed ID: 35649217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
    Carethers JM; Stoffel EM
    World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
    Sena LA; Fountain J; Isaacsson Velho P; Lim SJ; Wang H; Nizialek E; Rathi N; Nussenzveig R; Maughan BL; Velez MG; Ashkar R; Larson AC; Pritchard CC; Adra N; Bryce AH; Agarwal N; Pardoll DM; Eshleman JR; Lotan TL; Antonarakis ES
    Oncologist; 2021 Feb; 26(2):e270-e278. PubMed ID: 33215787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors.
    Mestrallet G; Brown M; Bozkus CC; Bhardwaj N
    Front Immunol; 2023; 14():1210164. PubMed ID: 37492581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
    Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
    J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
    Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.
    Viale G; Trapani D; Curigliano G
    Biomed Res Int; 2017; 2017():4719194. PubMed ID: 28770222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
    J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer neoantigens as potential targets for immunotherapy.
    Ma W; Pham B; Li T
    Clin Exp Metastasis; 2022 Feb; 39(1):51-60. PubMed ID: 33950415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.